LUPRON DEPOT® (leuprolide acetate for depot suspension) 7.5 mg for 1‑month, 22.5 mg for 3-month, 30 mg for 4‑month, and 45 mg for 6‑month administration are indicated for the palliative treatment of advanced prostatic cancer.
US-LUPR-190307
Please see accompanying Full Prescribing Information.
LUPRON DEPOT [package insert]. North Chicago, IL: AbbVie Inc; 2019.
U.S. Food & Drug Administration. Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed October 8, 2019.
Data on file. AbbVie Inc. IQVIA NSP data, September 2019.